Search results
Results from the WOW.Com Content Network
Enadenotucirev has also been modified with additional genes using the tumor-specific immuno-gene therapy (T-SIGn) platform to develop novel cancer gene therapy agents. [citation needed] The T-SIGn vectors at clinical study stage are: [citation needed]
Personalized mRNA cancer vaccine therapy is a therapy that uses a personalized cancer vaccine based on mRNA vaccine technology to target existing tumors in patients. As of 2024, number of mRNA cancer vaccines are in clinical trials, of which many are personalized therapies based on engineering mRNA-mediated immune response that targets the patient's particular strain of cancer cells.
NeuVax has been tested as adjuvant treatment in nearly 200 breast cancer patients over a total of 5 years, and has shown to be safe and effective in Phase 2 trials. [6] As a result, two additional NeuVax trials registered or underway are: (1) a 700 patient Phase 3 trial for FDA approval - not yet recruiting [2] [needs update] and (2) a 300 patient Phase 2 trial studying the combination of ...
The novel vaccine uses proteins unique to people’s tumors to train their immune systems to recognize cancer cells and then fight and hopefully kill the cells.
The results showed that a vaccine created based on a person's tumor cells can teach T-cells how to fight the melanoma with a 44% reduction in risk of recurrence of cancer and death.
Imugene Ltd is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Imugene's unique platform technologies seeks to harness the body's immune system against tumours, potentially achieving a similar or greater effect ...
Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified ...
Racotumomab [1] [2] (trade name Vaxira) is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio (R and Research in Computational Biology), an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National ...